DaVita Inc. (NYSE:DVA) Shares Sold by Coastline Trust Co

Coastline Trust Co decreased its holdings in DaVita Inc. (NYSE:DVA) by 79.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 360 shares of the company’s stock after selling 1,390 shares during the quarter. Coastline Trust Co’s holdings in DaVita were worth $59,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in DVA. Empowered Funds LLC grew its stake in shares of DaVita by 25.6% during the third quarter. Empowered Funds LLC now owns 5,824 shares of the company’s stock worth $955,000 after acquiring an additional 1,187 shares during the last quarter. Huntington National Bank boosted its stake in DaVita by 39.1% in the 3rd quarter. Huntington National Bank now owns 768 shares of the company’s stock worth $126,000 after purchasing an additional 216 shares in the last quarter. KBC Group NV grew its position in DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after purchasing an additional 67,250 shares during the last quarter. Chase Investment Counsel Corp increased its stake in DaVita by 56.3% during the 3rd quarter. Chase Investment Counsel Corp now owns 33,084 shares of the company’s stock valued at $5,423,000 after purchasing an additional 11,912 shares in the last quarter. Finally, Verus Capital Partners LLC purchased a new position in shares of DaVita in the third quarter worth $213,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Up 3.9 %

Shares of DVA stock opened at $160.33 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. DaVita Inc. has a twelve month low of $92.68 and a twelve month high of $168.50. The stock has a 50 day moving average of $157.78 and a 200 day moving average of $147.56. The stock has a market cap of $13.15 billion, a P/E ratio of 17.30, a P/E/G ratio of 0.90 and a beta of 0.89.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.85 earnings per share. As a group, sell-side analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the transaction, the chief financial officer now owns 111,481 shares in the company, valued at approximately $17,286,243.86. This trade represents a 36.48 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Javier Rodriguez sold 9,881 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the sale, the chief executive officer now directly owns 887,835 shares of the company’s stock, valued at $144,583,929.75. The trade was a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 156,086 shares of company stock valued at $24,807,161 in the last three months. 2.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays increased their price objective on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. UBS Group lifted their target price on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. TD Cowen increased their price target on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, Bank of America upped their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.